LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Peptidomics of Cancer-Derived Enzyme Products
- 1st Edition, Volume 42 - October 18, 2017
- Editors: Tony Y. Hu, Fuyuhiko Tamanoi
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 2 6 3 8 - 7
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 2 6 3 9 - 4
Peptidomics of Cancer-Derived Enzyme Products, Volume 42, the latest in The Enzymes series, is ideal for researchers in biochemistry, molecular and cell biology, pharmacology, an… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePeptidomics of Cancer-Derived Enzyme Products, Volume 42, the latest in The Enzymes series, is ideal for researchers in biochemistry, molecular and cell biology, pharmacology, and cancer, with this volume featuring high-caliber, thematic articles on the topic of peptidomics of cancer-derived enzyme products. Specific chapters cover Circulating peptidome and tumor-resident proteolysis, Colon tumor secretopeptidome, Chemoenzymatic method for glycomics, Human plasma peptidome for pancreatic cancer, Lipoproteomics and quantitative proteomics, Salivaomics: Protein markers/extracellular RNA/DNA in saliva, and Enzyme-responsive vectors for cancer therapy.
- Presents some of the most recent advances in the identification and function of enzymes changes in cancer
- Features authoritative expertise from recognized contributors to the field
Researchers, students and professors interested in or learning about/teaching peptidomics analysis for cancer therapy
- No. of pages: 188
- Language: English
- Edition: 1
- Volume: 42
- Published: October 18, 2017
- Imprint: Academic Press
- Hardback ISBN: 9780128126387
- eBook ISBN: 9780128126394
TH
Tony Y. Hu
Dr. Hu’s research focuses on developing and validating integrated nanotechnique-based strategies for marker discovery and molecular diagnostics in peripheral blood samples to provide a translatable solution for personalized medicine. His innovations aim to fill current gaps in early detection, real-time therapy monitoring and effective prognostics. He has assembled a diverse team with backgrounds in biochemistry, mass spectrometry, nanofabrication, and biomedical engineering to answer these needs.
Dr. Hu received his Ph.D. in Biomedical Engineering from the University of Texas at Austin where he focused on developing nanomaterials as biosensors for disease diagnosis. He has published more than 50 journal articles and has received five U.S. patents (issued and pending) on these subjects since his first faculty appointment in 2011. Dr. Hu has also published four nanomedicine-related book chapters, and has given more than 40 seminars and invited presentations at major international scientific conferences. His research team has a history of grants from the NCI, NIAID, NICHD and DOD and awards from the Gates, Dunn, Kostas, and Cockrell family foundations. His team has in-depth knowledge of multiplex-detection method development for sample processing, mass spectrometry, biomarker identification and validation. This background ideally positions his team for a leadership role in these fields and for optimal clinical translation of their platforms for improved and comprehensive analysis of blood-based biomarkers that have broad potential clinical applications.
Affiliations and expertise
Associate Professor, Biodesign Institute, Arizona State University’s Virginia G. Piper Center for Personalized Diagnostics and ASU’s School of Biological and Health Systems Engineering, USAFT
Fuyuhiko Tamanoi
Fuyu Tamanoi is a biochemist who has served on the UCLA School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993. He became a full professor in 1997.
Affiliations and expertise
Biochemist, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USARead Peptidomics of Cancer-Derived Enzyme Products on ScienceDirect